<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218501</url>
  </required_header>
  <id_info>
    <org_study_id>MO1003</org_study_id>
    <nct_id>NCT03218501</nct_id>
  </id_info>
  <brief_title>A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus</brief_title>
  <official_title>A Phase II, Double-Blind, Randomized, Placebo-Controlled Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanwa Kagaku Kenkyusho Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanwa Kagaku Kenkyusho Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and dose response of SK-1405
      for the treatment of subjects with uremic pruritus receiving hemodialysis, during 2 weeks of
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Worst-itching Visual Analog Scale (VAS)</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Worst-itching Visual Analog Scale (VAS)</measure>
    <time_frame>1 week, 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Itch Severity Assessment</measure>
    <time_frame>1 week, 2 weeks, 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Sleep Quality Assessment</measure>
    <time_frame>1 week, 2 weeks, 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 5D Itch Scale</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Uremic Pruritus in Hemodialysis Patients</condition>
  <arm_group>
    <arm_group_label>SK-1405 high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SK-1405 high dose is to be administered orally once daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SK-1405 low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SK-1405 low dose is to be administered orally once daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is to be administered orally once daily for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SK-1405 high dose</intervention_name>
    <description>SK-1405 high dose is to be administered orally once daily for 2 weeks</description>
    <arm_group_label>SK-1405 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SK-1405 low dose</intervention_name>
    <description>SK-1405 low dose is to be administered orally once daily for 2 weeks</description>
    <arm_group_label>SK-1405 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is to be administered orally once daily for 2 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Receiving hemodialysis three times a week for at least 12 weeks

          -  Worst itching VAS in a day is 30 mm or more at least 5 days during the first
             observation period

          -  Mean worst itching VAS is 50 mm or more in both the first and second observation
             periods

        Exclusion Criteria:

          -  Complications that may affect the assessment of uremic pruritus

          -  Started or changed pruritus treatment within 13 days prior to starting observations

          -  Received ultraviolet treatment within 27 days prior to starting observations

          -  Uncontrollable hypertension, serious liver disease, serious heart disease, stroke, or
             malignant tumor

          -  Depression, schizophrenia, dementia, epilepsia, convulsive seizure, drug addiction, or
             alcoholism

          -  Pregnancy, or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>SANWA KAGAKU KENKYUSYO CO., LTD. Clinical development dept.</last_name>
    <phone>+81-52-951-8130</phone>
    <email>clinicaltrials@skk-net.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational site (there may be other sites in this country)</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uremic Pruritus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

